43 results about "Furazan" patented technology

The application relates to the technical field of solar energy, in particular to a self-cleaning solar photovoltaic panel and a preparation process thereof. The application adds anhydrous ethanol, ammonia water, deionized water, methyl triethoxysilane, tetraethyl orthosilicate and octadecyl trimethoxysilane to prepare silica sol. Then, tetra(2-hydroxyethoxy)silane, polypropylene glycol, toluene diisocyanate, betulin, 3,4-diamino furazan, silica sol and a catalyst stannous octoate are added to prepare a polymer. Glass, ethylene-vinyl acetate copolymer, a cell piece and ethylene-vinyl acetate copolymer are sequentially laid in layers; the laminated assembly is assembled with a frame to obtain a solar photovoltaic panel. Finally, a coating is prepared by taking the polymer as a raw material, and the coating is coated on the solar photovoltaic panel to obtain a finished product. The finished product has good hydrophobicity and antibacterial property, and therefore has a wide application prospect.

The invention relates to the field of chemical pharmacy, in particular to an aryl ketone derivative and furazan spliced conjugate as well as a preparation method and application thereof. The structural formula of the conjugate spliced by the aryl ketone derivative and the furazan is as shown in any one of formulas I-V: # imgabs0 # imgabs1 #. A coumarin skeleton is opened, and the conjugate spliced by the aryl ketone derivative and the furazan is designed and synthesized. The aryl ketone derivative and furazan combined conjugate disclosed by the invention is novel in structure, has the effect of highly selectively inhibiting the proliferation activity of P-gp overexpression drug-resistant tumor cells, and provides a new thought and direction for overcoming the multidrug resistance of the tumor cells caused by P-gp overexpression.

The invention provides a polypeptide and application thereof in photocatalytic nitrogen fixation, and belongs to the technical field of photocatalysts. The sequence of the polypeptide is N3y (NBD-yyy) or N3Y (NBD-YYY), NBD is 4-amino-7-nitrobenzofurazan, y is D-configuration tyrosine, Y is L-configuration tyrosine, and the amino group in the NBD is derived from HCl-removed carbon nitrogen coupling of NBD-Cl (4-chloro-7-nitrobenzofurazan) and free amino group on y or Y. The polypeptide provided by the invention can be prepared into an aqueous solution for assembling and adsorbing nitrogen, and forms a charge transfer compound with nitrogen. Under the condition of normal-temperature and normal-pressure natural illumination reaction for 6 hours, the ammonia gas generation efficiency of the photocatalyst is 61.8 mg <-1 > gcat <-1 > h <-1 >, the catalytic electron turnover number is 43.9, and the efficiency of the photocatalyst can be compared favorably with that of the current excellent non-metal inorganic material, metal or metal-organic photocatalyst.

The invention discloses a method for determining the solution concentration in the crystallization process of 3, 4-dinitrofurazan furoxan oxide, and relates to the technical field of energetic crystal materials. According to the method, an EasySampler and HPLC (High Performance Liquid Chromatography) combined method is utilized, the solubility of DNTF is measured, a standard curve of DNTF solution concentration and peak area is established by utilizing a high performance liquid chromatograph, then the EasySampler is utilized to sample a crystallization process and perform HPLC analysis, and then the solution concentration at each moment is calculated by utilizing an equation of the standard curve. According to the method, EasySampler equal interval sampling is combined with off-line HPLC (High Performance Liquid Chromatography) analysis, and a curve that the concentration of the main component of the solution changes along with the temperature is constructed. In the dominant period of crystal growth, the concentration change rate and the solid-liquid interface area are in an approximately linear relationship. The experimental data provides a necessary demonstration basis for subsequent improvement of a non-ideal system crystallization kinetics theory.

A one-pot method for the synthesis of disubstituted furoxans and a one-pot method for synthesis of diethyl furoxan dicarboxylate (DFD).

The invention relates to the technical field of nano preparations, in particular to self-assembled nanoparticles suitable for NO synergistic phototherapy and a preparation method and application of the self-assembled nanoparticles. The invention provides a novel furazan NO donor-silicon phthalocyanine photosensitizer conjugate or a furazan NO donor-hyaluronic acid conjugate, and a preparation method of the furazan NO donor-silicon phthalocyanine photosensitizer conjugate or the furazan NO donor-hyaluronic acid conjugate. The furazan NO donor-silicon phthalocyanine photosensitizer conjugate is subjected to self-assembly preparation, or the furazan NO donor-hyaluronic acid conjugate wraps a photosensitizer or other drugs to obtain the self-assembly nanoparticles suitable for NO synergistic therapy. The nanoparticle realizes space-time co-transport of NO and the photosensitizer, has a controllable drug release behavior, and improves the tumor treatment effect. The nanoparticles can generate NO and ROS in cells, the NO and the ROS react with each other to form an active nitrogen substance, heat released by phototherapy and ROS promote release of NO, and the nanoparticles and NO cooperate to induce apoptosis of breast cancer cells or cervical cancer cells.

The invention relates to the technical field of ionic couple and electrochemical synergistic synthesis, in particular to 3, 3 '-diamino-4, 4'-azofurazan and an ionic couple and electrochemical synergistic synthesis method thereof, and the synthesis method comprises the following steps: 1, preparing CC-Co3O4: adopting nitric acid hexahydrate, ammonium fluoride, urea and carbon cloth as raw materials, and preparing the CC-Co3O4 through a hydrothermal method; 2, preparing an acidic solution of 3, 4-diaminofurazan to obtain a first solution; 3, preparing an acid solution of Ce < 4 + > to obtain a second solution; and 4, carrying out an electrocatalytic oxidation reaction by taking CC-Co3O4 as an anode, a platinum sheet as a counter electrode and the first solution as an electrolyte, dropwise adding the second solution into the electrolyte in the electrocatalytic process, and stirring, centrifuging, washing, drying and grinding after the second solution is dropwise added to obtain the 3, 3 '-diamino-4, 4'-azofurazan.

The application provides a salidroside derivative, a preparation method and application thereof. The structure of the salidroside derivative is shown in formula I: wherein R1 is selected from H and carbonyl; R2 is selected from H and X is selected from O and NH; m is an integer of 3-6, and n is 0 or an integer of 3-6. The salidroside derivative has excellent antitumor activity, and the activity is obviously improved compared with salidroside. The preparation method of the salidroside derivative has mild reaction conditions, uses low-toxicity reagents, and has easily-obtained raw materials and convenient post-treatment.

NO-S-S-AurB conjugates, a preparation method therefor, and the use of the NO-S-S-AurB conjugates in drugs having anti-TNBC activity and selectivity, belonging to the technical field of medicines. In particular, the NO-S-S-AurB conjugates are synthesized on the basis of self immolation strategy, and a benzenesulfonyl furazan nitric oxide NO donor is combined with AurB to prepare a twin drug, so as to synthesize a plurality of NO-S-S-AurB conjugates, structures of the NO-S-S-AurB conjugates being confirmed by means of spectrum characterization. Also provided is the preparation method for the NO-S-S-AurB conjugates, which involves a reasonable route, achieves high product yield, facilitates separation and achieves high purity. Since tumor tissue has a characteristic of high glutathione (GSH) expression, a GSH-sensitive disulfide bond linking chain in the series of NO-S-S-AurB conjugates can be self-immolated, thereby remarkably improving the anti-TNBC activity and selectivity of the parent drug AurB.

The application discloses a Z-(4-amino-1,2,5 furazanyl)-5-nitrotetrazole-oxime compound, a synthesis method and application. The structural formula of the disclosed compound is shown as (I). The density and the theoretical detonation velocity of the Z-(4-amino-1,2,5 furazanyl)-5-nitrotetrazole-oxime of the application are significantly improved compared with existing substances, and the Z-(4-amino-1,2,5 furazanyl)-5-nitrotetrazole-oxime can be used as a new energetic material.

The present invention provides processes for preparing a compound of formula I and pharmaceutically acceptable salts thereof,comprising deprotecting a compound of formula IIwherein each R3 independently represents a tertiary alkyl group, preferably wherein each R3 is tertiary butyl. The invention also provides intermediates useful for preparing compounds of formula I and processes for preparing these intermediates. Additionally the invention provides polymorphic forms of the dichloride salt of the compound of formula I and their use in the treatment of proliferative disorders.

The invention provides a synthesis method of 3, 3-bis (4-nitrofurazan-3-oxymethyl) oxetane, which comprises the following steps: adding 3-nitro-4-hydroxyfurazan, 3, 3-dibromomethyl oxetane, an alkaline donor and a phase transfer catalyst into a polar aprotic solvent, stirring and reacting at 60-100 DEG C for 0.5-4 hours, extracting, washing with water, drying, filtering, evaporating the solvent to dryness and recrystallizing to obtain 3, 3-bis (4-nitrofurazan-3-oxymethyl) oxetane, thereby obtaining the 3, 3-bis (4-nitrofurazan-3-oxymethyl) oxetane. Obtaining a finished product. According to the preparation method, 3-nitro-4-hydroxyfurazan and 3, 3-dibromomethyl oxetane are taken as raw materials, and the 3, 3-bis (4-nitrofurazan-3-oxymethyl) oxetane can be obtained by performing substitution reaction through'one-pot boiling 'under an alkaline system; the method has the advantages of easily available reaction raw materials, simple reaction steps, small environmental pollution and continuous operation; by controlling the reaction conditions, the product can be completely converted into a disubstituted product through one-step reaction, the purity is high, the reaction time is short, and the product with the purity not less than 98% can be directly obtained after recrystallization; the reaction route is more efficient and convenient, and industrial continuous production is facilitated.

The present invention relates to furazidin for vaginal use in the treatment of a bacterial vaginal infection. Preferably, the bacterial vaginal infection is caused by Gardnerella vaginalis and / or Atopobium vaginae bacteria.

The application discloses a method for synthesizing 3-amino furazan-4-carboxylic acid from 1,2,3-propanetriol, and belongs to the technical field of chemical engineering and chemistry.The method solves the problems of the prior art, such as the use of toxic raw materials, highly toxic and flammable and explosive reagents, and the lack of greenness and safety, etc.The 1,2,3-propanetriol and a hydroxylamine solution are dissolved in an alkaline aqueous phase, and through adjustment of the reaction temperature, the 1,2,3-propanetriol successively undergoes catalytic reaction, dehydration reaction and neutralization reaction, and finally 3-amino furazan-4-carboxylic acid is synthesized, with a yield of 55%.The method has the advantages of safe and non-toxic raw materials, short synthesis reaction time, simple reaction steps, easy control of reaction temperature, high product yield, less pollutants, etc.Compared with the traditional method for synthesizing 3-amino furazan-4-carboxylic acid, the method saves production cost, the product preparation process is green and environmentally friendly, and is suitable for the green and sustainable development of industrial production of 3-amino furazan-4-carboxylic acid.

The invention discloses a compound with a benzimidazole-amino furazan-oxadiazole skeleton as well as a preparation method and application of the compound. The structure of the compound is shown in general formulas I and II. According to the present invention, butyrylcholine esterase inhibition activity, Nrf2 activation activity, in vitro pharmacodynamic experiment and Morris water maze experiment are adopted as carriers to evaluate the treatment of Alzheimer's disease (especially moderate and severe Alzheimer's disease) by using the compounds represented by the general formulas I and II, and the results show that the compounds have good in vitro and in vivo activity and extremely high selectivity; the compound can be used as a candidate lead compound for further development of an anti-Alzheimer's disease effect by selectively inhibiting butyrylcholine esterase and activating Nrf2.

The invention relates to 1: 2 metal complex red, a preparation method thereof and a dye composition, the preparation method comprises the following steps: mixing 5-sulfonic acid-7-nitrobenzofurazan, an acid-binding agent, a Lewis acid catalyst and water, adjusting the pH value to 1.9-2.1, and carrying out a ring-opening reaction, the molar ratio of 5-sulfonic acid-7-nitrobenzofurazan to the Lewis acid catalyst being 1: 0.012-0.017; pyrazolone shown in the formula (I) is added into a ring-opening reaction product, a coupling reaction is conducted under the condition that the pH ranges from 7.0 to 8.0, in the formula (I), R1 is selected from phenyl or tolyl, and R2 is selected from methyl or ethyl; a chromium solution is dropwise added into the coupling product, the molar ratio of the chromium element in the chromium solution to the coupling product is 1: (1.9-2.1), the temperature is controlled to be 75-80 DEG C in the dropwise adding process, the concentration of Cr < 3 + > is 0.02-0.03 mol / L, the temperature is increased to 95-97 DEG C after dropwise adding is completed, the pH is adjusted to 4.5-4.8, a complexation reaction is conducted, and the 1: 2 metal complex red shown in the formula (II) is obtained. The 1: 2 metal complex red with low environmental protection risk, high dyeing performance and good batch stability can be prepared.

This invention provides a method for synthesizing 3-(4-azidofurazan-3-oxomethyl)-3-azidomethyloxetane, its structural formula is shown below: The method includes the following steps: Step 1, 3-nitro-4-hydroxyfurazan, 3,3-dibromomethyloxetane, a basic donor and a phase transfer catalyst are added to a polar aprotic solvent, and the mixture is stirred at 45-85°C for 0.5-2 hours. Then, the mixture is extracted, washed with water, dried, filtered, the solvent is evaporated, and recrystallized to obtain 3-(4-azidofurazan-3-oxomethyl)-3-azidomethyloxetane. 3-(4-nitrofurazan-3-oxomethyl)-3-bromomethyloxetane; the 3-(4-nitrofurazan-3-oxomethyl)-3-bromomethyloxetane obtained in steps 2 and 1 and the azidating agent are added to a polar aprotic solvent and stirred at room temperature for 0.5-1.5 h. Then, the mixture is extracted, washed with water, dried, filtered, and the solvent is evaporated to obtain the final product. The 3-(4-azidofurazan-3-oxomethyl)-3-azidomethyloxetane prepared by this invention can be used as an energetic binder or an energetic initiator.

The present invention provides processes for preparing a compound of formula I and pharmaceutically acceptable salts thereof,comprising deprotecting a compound of formula IIwherein each R3 independently represents a tertiary alkyl group, preferably wherein each R3 is tertiary butyl. The invention also provides intermediates useful for preparing compounds of formula I and processes for preparing these intermediates. Additionally the invention provides polymorphic forms of the dichloride salt of the compound of formula I and their use in the treatment of proliferative disorders.

The present invention relates to a tetraaminobifurazan energetic compound and a preparation method thereof, belonging to the technical field of energetic materials. The purpose of the present invention is to solve the problem of few amino substitution sites in the furazan skeleton in the prior art. The present invention provides a tetraaminobifurazan energetic compound and a preparation method thereof; this method uses malononitrile as a starting point to obtain 3-aminooxime-4-aminofurazan, and then obtains the target tetraamino-containing bifurazan energetic compound through a simple one-pot reaction, and there is no need to purify the intermediate. On the one hand, the present invention breaks through the number of amino groups in the current furazan-based energetic compounds and obtains a bifurazan energetic compound containing four amino groups. On the other hand, the present invention discloses a preparation method for obtaining a furazan ring skeleton compound containing multiple amino groups.

The invention discloses a method for preparing 6-nitrobenzofuroxan by a one-pot method, which comprises the following steps: firstly, mixing 2, 4-dichloro-1, 3, 6-trinitrobenzene and monobasic organic acid according to a mass ratio of 1: (8-20) until the 2, 4-dichloro-1, 3, 6-trinitrobenzene and the monobasic organic acid are dissolved; the preparation method comprises the following steps: mixing 2, 4-diazido-1, 3, 6-trinitrobenzene and 2, 4-dichloro-1, 3, 6-trinitrobenzene according to a molar ratio of 1: (0.5-2), adding sodium azide into a mixed solution obtained in the step 1, and reacting at 20-50 DEG C for 0.5-2 hours to obtain an acid solution of 2, 4-diazido-1, 3, 6-trinitrobenzene, with the molar ratio of 2, 4-dichloro-1, 3, 6-trinitrobenzene to sodium azide being 1: (0.5-2); then, the temperature of the acid solution of the 2, 4-diazido-1, 3, 6-trinitrobenzene is increased to 70 DEG C to 120 DEG C, and a reaction is conducted for 0.5 h to 3 h at the temperature; and finally, carrying out rotary evaporation on the reaction liquid, removing the monobasic organic acid to obtain orange powder, adding water, washing, filtering and drying to obtain the 6-nitrobenzofuroxan. According to the preparation method disclosed by the invention, the 6-nitrobenzofuroxan can be obtained by carrying out azidation reaction and pyrolysis condensation reaction on 2, 4-dichloro-1, 3, 6-trinitrobenzene only by using one organic solvent, so that the generation of organic waste liquid is greatly reduced.

Embodiments of this disclosure describe the synthesis of 4-amino-3 bromocarbohydroxymoyl-1,2,5-oxadiazole from a precursor solution in methanol. The synthesis uses 4-amino-3-aminocarbohydroxymoyl-1,2,5-oxadiazole as the starting material. The procedure involves the sequential treatment of the starting material in methanol with hydrobromic acid, cuprous bromide, and sodium nitrite. This treatment results in the precipitation of a new chemical entity, the bromo-oxime 4-amino-3-bromocarbohydroxymoyl-1,2,5-oxadiazole. Upon obtaining the bromo-oxime derivative, the method further facilitates the production of 3,4-bis(4-amino-1,2,5-oxadiazol-3-yl)-1,2,5-oxadiazole-N-oxide (furoxan derivative) through dimerization in a biphasic reaction medium consisting of ethyl acetate and water, with potassium carbonate serving as a key reactant. This innovative method offers a streamlined approach, enabling the direct use of the intermediate oxadiazole derivative without the need for additional purification, leading to the desired furoxan derivative. This synthesis method stands out for its efficiency, high-purity yield, and fewer steps, offering potential applications in various chemical industries.

The invention provides an iodine-containing energetic bactericidal compound based on a furazan skeleton as well as a preparation method and application of the iodine-containing energetic bactericidal compound, and belongs to the technical field of energetic materials. The compound comprises any one of the following components: 3, 4-diiodo-1, 2, 5-oxadiazole, 4-diiodo-1, 2, 5-oxadiazole, 4-diiodo-1, 2, 2, 3, 3 '-diiodo-4, 4'-azofurazan; the preparation method comprises the following steps: adding 2, 3 '-diiodo-4, 4'-azoxyfurazan into a reaction kettle; the preparation method comprises the following steps: adding 1, 3-iodo-4-nitramine-1, 2, 5-oxadiazole; by combining the furazan skeleton with high nitrogen and oxygen content with the iodine atom and the energetic group, the detonation performance and enthalpy of formation of the compound are remarkably improved. The compound has high iodine content (more than 45%), high oxygen balance (gt;-8%) and high detonation velocity (up to 6505 m.s), and is suitable for preparing efficient energetic bactericidal materials.

NO-S-S-AurB conjugates, a preparation method therefor, and the use of the NO-S-S-AurB conjugates in drugs having anti-TNBC activity and selectivity, belonging to the technical field of medicines. In particular, the NO-S-S-AurB conjugates are synthesized on the basis of self immolation strategy, and a benzenesulfonyl furazan nitric oxide NO donor is combined with AurB to prepare a twin drug, so as to synthesize a plurality of NO-S-S-AurB conjugates, structures of the NO-S-S-AurB conjugates being confirmed by means of spectrum characterization. Also provided is the preparation method for the NO-S-S-AurB conjugates, which involves a reasonable route, achieves high product yield, facilitates separation and achieves high purity. Since tumor tissue has a characteristic of high glutathione (GSH) expression, a GSH-sensitive disulfide bond linking chain in the series of NO-S-S-AurB conjugates can be self-immolated, thereby remarkably improving the anti-TNBC activity and selectivity of the parent drug AurB.

The invention discloses a benzofurazan derivative as well as a preparation method and application thereof, and belongs to the technical field of medicines. The structure of the benzofurazan derivative is shown in the specification. The compound has the beneficial effects that IC50 values of proliferation inhibition effects of part of compounds (compounds A3, A4, A11, A12, A13, A14, A15, A25, A31, A32 and A39) on four tumor cells Hela, A549, HCT116 and MKN45 are all superior to those of a prototype compound XI-006 to different degrees, the inhibition effects of the compound A3 on the Hela cell and the HCT116 cell are the strongest and are respectively superior to those of the compound XI-006 by 10 times and 3.5 times, and the inhibition effects of the compound A39 on the A549 cell and the MKN45 cell are the strongest and are respectively superior to those of the compound XI-006 by 2.8 times and 10.8 times.

The invention discloses a 3, 3 '-diazido ethoxy-4, 4'-azofurazan compound as well as a preparation method and application thereof, and belongs to the technical field of energetic materials, and the molecular structural formula of the 3, 3 '-diazido ethoxy-4, 4'-azofurazan compound is shown as (I). According to the preparation method, 3, 3 '-dinitro-4, 4'-azofurazan and 2-azidoethanol are used as raw materials, the temperature is raised to 35-37 DEG C, and the 3, 3 '-diazido ethoxy-4, 4'-azofurazan compound is prepared through a reaction, and the compound belongs to insensitive energetic materials, has the advantages of being low in sensitivity, good in thermal stability and the like and is mainly used in the fields of solid propellants, propellant powder and the like.

The invention discloses a furazan hydrazone energetic compound and a synthesis method thereof, the furazan hydrazone energetic compound is named as 2-bis ((3-methyl-4-furazan)-methylene hydrazino)-1-oxalyl hydrazine, and the furazan hydrazone energetic compound is expected to be used for high-energy low-sensitivity energetic materials. The invention also provides a synthesis method of the compound, which comprises the following steps: by taking trans-butenal containing an aldehyde group as a substrate, reacting with sodium nitrite under the acidic conditions of formic acid and the like, carrying out ring closing to obtain 3-methyl-4-formyl-2-furazan, and finally, carrying out ring closing to obtain the 3-methyl-4-formyl-2-furazan. The furazan hydrazone compound is constructed by carrying out condensation reaction on the aldehyde group, oxalyl hydrazine and other multi-hydrazino structure compounds. The synthesis method disclosed by the invention has the characteristics of simplicity and convenience in operation, high safety, high yield and the like.

To provide a composition for light-emitting device that enables production of a light-emitting device with high productivity while maintaining device characteristics and reliability of the light-emitting device.SOLUTION: The present invention relates to a composite for light-emitting device which is obtained by mixing a plurality of organic compounds. The composition for light-emitting device is obtained by mixing a first organic compound having a diazine skeleton (preferably, a benzofloadiazine skeleton, a naphthoflodiazine skeleton, a phenanthroflodiazine skeleton, a benzothienodiazine skeleton, a naphthothienodiazine skeleton or a phenanthrothienodiazine skeleton), and a second organic compound as an aromatic amine compound together.SELECTED DRAWING: Figure 2

The invention belongs to the technical field of medicines, and discloses a hydroxime compound derived from an aqueous extract of heads of angelica sinensis, a dehydrated furazan compound of the hydroxime compound, and preparation and application of the hydroxime compound and the dehydrated furazan compound. In particular discloses a hydroxime compound, a dehydrated furazan compound thereof, pharmaceutically acceptable salts of the dehydrated furazan compound and a pharmaceutical composition of the dehydrated furazan compound. The invention also discloses application of the compound in preparation of medicines for treating arthritis, asthma, chronic obstructive pneumonia, pneumonia, cystic fibrosis, diabetes, obesity, hypercholesterolemia, contact dermatitis, psoriasis, atopic dermatitis, stasis dermatitis, seborrheic dermatitis, neurodermatitis and the like, inflammatory enteritis, multiple sclerosis, Parkinson's disease, cardiovascular disease, autoimmune disease, gout and the like. The invention also relates to applications in medicines or health-care products for treating hyperuricemia and cancers. Activity evaluation of a cell model for starting reporter gene expression by using an NF-kappa B reaction element proves that the compound can significantly inhibit NF-kappa B induced transcriptional regulation and is expected to become a therapeutic drug for treating the various diseases.

The invention relates to the technical field of explosives, in particular to an energetic binder coated DNTF explosive and a preparation method thereof.The preparation method comprises the following steps that S1, an energetic binder is dissolved in an organic solvent, and an energetic binder solution with the mass percent being 1%-20% is obtained; s2, putting 3, 4-dinitrofurazan furazan (DNTF) powder into water, heating, stirring and dispersing, so as to obtain DNTF turbid liquid; s3, dropwise adding the energetic binder solution prepared in the step S1 into the DNTF suspension prepared in the step S2, stirring, then carrying out vacuumizing treatment, and after the organic solvent is volatilized, sequentially carrying out suction filtration, washing and sieving to obtain DNTF explosive particles; the problem that the energy output of the DNTF explosive is reduced in the existing DNTF explosive packaging technology, so that the further application of the DNTF explosive in the application scene requiring high performance and high safety is limited is solved.

This invention discloses a novel fluoro-dinitrofuranzan-type energetic compound, its preparation method, and its applications. The preparation method of the novel fluoro-dinitrofuranzan-type energetic compound provided by this invention includes the following steps: First, the dipotassium salt of 4-gamma-dinitro-3-nitraminofuran from methylene chelate is fluorinated and then hydrolyzed with an alkaline solution to obtain the potassium salt of 4-fluoro-dinitro-3-nitraminofuran. This potassium salt is then acidified to obtain 4-fluoro-dinitro-3-nitraminofuran, which is then reacted with ammonia and hydroxylamine, respectively, to obtain its corresponding ammonium and hydroxylamine salts. The novel fluoro-dinitrofuranzan-type energetic compound provided by this invention has the advantages of high oxygen content, high theoretical energy, and good thermal stability, and can be used as a high-energy oxidant in the field of propellants.